Venetoclax plus '2+5' modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis

Article Hematology

Venetoclax plus 3+7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial

Huafeng Wang et al.

Summary: This study investigated the activity and safety of venetoclax plus 3+7 daunorubicin and cytarabine chemotherapy in adults with acute myeloid leukemia. The findings showed that the DAV regimen is an effective induction therapy for newly diagnosed adults with acute myeloid leukemia, resulting in a high rate of complete remission.

LANCET HAEMATOLOGY (2022)

添加到收藏夹

Article Hematology

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Doehner et al.

Summary: The 2010 and 2017 editions of the European LeukemiaNet recommendations for AML diagnosis and management are widely recognized. There have been major advances in our understanding of AML, including disease classification updates, improvements in genomic diagnostics, and the development of new therapeutic agents. This update includes a revised genetic risk classification, response criteria, and treatment recommendations.

BLOOD (2022)

添加到收藏夹

Article Hematology

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Abhishek Maiti et al.

Summary: Assessment of measurable residual disease (MRD) provides prognostic information in acute myeloid leukemia (AML). However, it remains unclear how MRD status impacts survival outcomes in older/unfit patients receiving first-line therapy with 10-day decitabine and venetoclax. This study found that achieving a negative MRD at 1, 2, and 4 months post-treatment significantly improved survival in this patient population.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Hematology